NovoCure (BMV:NVCR N) - Stock Price, News & Analysis

NVCR N Stock Overview

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. More details

NVCR N fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 7.1% per year

Risk Analysis

Earnings are forecast to decline by an average of 5% per year for the next 3 years

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

NovoCure Limited Competitors

MeHow Innovative

SZSE:301363

CN¥12.3b

Qingdao Haier BiomedicalLtd

SHSE:688139

CN¥10.5b

Integra LifeSciences Holdings

NasdaqGS:IART

US$1.8b

Shinva Medical InstrumentLtd

SHSE:600587

CN¥10.7b

Price History & Performance

Summary of all time highs, changes and price drops for NovoCure
Historical stock prices
Current Share Price	US$275.39
52 Week High	US$2,140.47
52 Week Low	US$275.39
Beta	0.52
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-86.68%

Recent updates

Shareholder Returns

	NVCR N	MX Medical Equipment	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how NVCR N performed against the MX Medical Equipment industry.

Return vs Market: Insufficient data to determine how NVCR N performed against the MX Market.

Price Volatility

Is NVCR N's price volatile compared to industry and market?
NVCR N volatility
NVCR N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: NVCR N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NVCR N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	1,320	Asaf Danziger	www.novocure.com

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited Fundamentals Summary

How do NovoCure's earnings and revenue compare to its market cap?
NVCR N fundamental statistics
Market cap	Mex$27.09b
Earnings (TTM)	-Mex$3.35b
Revenue (TTM)	Mex$8.56b

3.2x

P/S Ratio

-8.1x

P/E Ratio

Is NVCR N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVCR N income statement (TTM)
Revenue	US$503.98m
Cost of Revenue	US$124.00m
Gross Profit	US$379.98m
Other Expenses	US$577.25m
Earnings	-US$197.27m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.85
Gross Margin	75.40%
Net Profit Margin	-39.14%
Debt/Equity Ratio	144.3%

How did NVCR N perform over the long term?

See historical performance and comparison

NVCR N Stock Overview

Rewards

Risk Analysis

NovoCure Limited Competitors

SZSE:301363

CN¥12.3b

SHSE:688139

CN¥10.5b

NasdaqGS:IART

US$1.8b

SHSE:600587

CN¥10.7b

Price History & Performance

Recent News & Updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

Recent updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer